By
Kevin Grogan
Published: July 15, 2013, 11:06 p.m.·
Tags:
None
Otsuka Pharmaceutical Co says that enrollment has begun for "a ground-breaking clinical programme" looking at its investigational drug delamanid for paediatric multidrug-resistant tuberculosis (MDR-TB).
Read More →